Heritage Investors Management Has Cut Price T Rowe Group (TROW) Holding; Aratana Therapeutics, Inc. (PETX) Covered By 5 Bulls

February 24, 2018 - By Adrian Erickson

Among 8 analysts covering Aratana Therapeutics (NASDAQ:PETX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Aratana Therapeutics had 18 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Thursday, June 8 report. The rating was maintained by Barclays Capital with “Overweight” on Thursday, August 11. The stock has “Buy” rating by Jefferies on Friday, August 19. The firm earned “Hold” rating on Monday, December 18 by Stifel Nicolaus. The firm has “Buy” rating given on Tuesday, January 16 by H.C. Wainwright. The firm has “Buy” rating given on Friday, August 4 by Jefferies. The stock of Aratana Therapeutics, Inc. (NASDAQ:PETX) has “Buy” rating given on Friday, November 3 by Jefferies. The company was initiated on Thursday, February 4 by Credit Suisse. The stock has “Hold” rating by Craig Hallum on Friday, September 25. Jefferies maintained the stock with “Buy” rating in Wednesday, November 15 report. See Aratana Therapeutics, Inc. (NASDAQ:PETX) latest ratings:

16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
27/12/2017 Broker: C.L. King Rating: Hold Initiate
18/12/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $6.0 Maintain
15/11/2017 Broker: Jefferies Rating: Buy New Target: $8.5 Maintain
17/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10 Initiates Coverage On
03/11/2017 Broker: Jefferies Rating: Buy New Target: $8.0 Maintain
23/10/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $7.0 Maintain

Heritage Investors Management Corp decreased Price T Rowe Group Inc (TROW) stake by 4.61% reported in 2017Q3 SEC filing. Heritage Investors Management Corp sold 12,458 shares as Price T Rowe Group Inc (TROW)’s stock declined 0.66%. The Heritage Investors Management Corp holds 257,982 shares with $23.39M value, down from 270,440 last quarter. Price T Rowe Group Inc now has $27.45 billion valuation. The stock increased 1.70% or $1.88 during the last trading session, reaching $112.3. About 1.54M shares traded. T. Rowe Price Group, Inc. (NASDAQ:TROW) has declined 4.22% since February 24, 2017 and is downtrending. It has underperformed by 20.92% the S&P500.

Investors sentiment decreased to 0.91 in 2017 Q3. Its down 0.02, from 0.93 in 2017Q2. It dived, as 48 investors sold TROW shares while 247 reduced holdings. 84 funds opened positions while 185 raised stakes. 171.36 million shares or 2.33% less from 175.45 million shares in 2017Q2 were reported. Vaughan David Investments Inc Il holds 1.69% in T. Rowe Price Group, Inc. (NASDAQ:TROW) or 384,746 shares. The Michigan-based Ls Inv Advsr Lc has invested 0.21% in T. Rowe Price Group, Inc. (NASDAQ:TROW). 74,680 are held by Fort Washington Investment Advisors Oh. Guggenheim Capital Limited Liability Co owns 687,072 shares. Covington Cap reported 19,583 shares. Davenport & Ltd Liability Corp holds 0% or 3,922 shares. Fairfield Bush & accumulated 3,480 shares. Sun Life Fincl has invested 0.05% in T. Rowe Price Group, Inc. (NASDAQ:TROW). Jpmorgan Chase Co holds 11.97 million shares. Reynders Mcveigh Mngmt Lc holds 0.04% of its portfolio in T. Rowe Price Group, Inc. (NASDAQ:TROW) for 3,025 shares. Renaissance Grp Limited Liability Company holds 397,891 shares or 1.24% of its portfolio. Plante Moran Fin Advisors Ltd Llc reported 0% of its portfolio in T. Rowe Price Group, Inc. (NASDAQ:TROW). Peapack Gladstone has invested 0.04% in T. Rowe Price Group, Inc. (NASDAQ:TROW). Hedeker Wealth Ltd Liability reported 38,805 shares. Commercial Bank Va accumulated 5,263 shares.

Analysts await T. Rowe Price Group, Inc. (NASDAQ:TROW) to report earnings on April, 24. They expect $1.63 EPS, up 38.14% or $0.45 from last year’s $1.18 per share. TROW’s profit will be $398.44 million for 17.22 P/E if the $1.63 EPS becomes a reality. After $1.52 actual EPS reported by T. Rowe Price Group, Inc. for the previous quarter, Wall Street now forecasts 7.24% EPS growth.

Heritage Investors Management Corp increased Home Depot Inc (NYSE:HD) stake by 3,128 shares to 142,446 valued at $23.30 million in 2017Q3. It also upped Celgene Corp (NASDAQ:CELG) stake by 2,900 shares and now owns 21,250 shares. Shire Plc (NASDAQ:SHPG) was raised too.

Since August 31, 2017, it had 0 insider purchases, and 8 sales for $16.11 million activity. $377,321 worth of T. Rowe Price Group, Inc. (NASDAQ:TROW) shares were sold by WHITTEMORE ANNE M. Shares for $84,292 were sold by Hiebler Jessica M. On Wednesday, December 13 the insider Wiese Edward A sold $3.06M. HRABOWSKI FREEMAN A III had sold 4,000 shares worth $406,356 on Thursday, December 14. MORELAND KENNETH V had sold 13,041 shares worth $1.18 million on Monday, October 2. Shares for $700,052 were sold by Alderson Christopher D on Friday, December 8.

Among 15 analysts covering T. Rowe Price Group Inc (NASDAQ:TROW), 5 have Buy rating, 2 Sell and 8 Hold. Therefore 33% are positive. T. Rowe Price Group Inc had 75 analyst reports since August 5, 2015 according to SRatingsIntel. As per Tuesday, August 9, the company rating was maintained by Barclays Capital. The firm has “Positive” rating by Susquehanna given on Thursday, September 3. RBC Capital Markets maintained the stock with “Sector Perform” rating in Friday, October 23 report. The firm has “Buy” rating given on Friday, October 23 by Deutsche Bank. As per Thursday, December 21, the company rating was maintained by Keefe Bruyette & Woods. On Tuesday, June 20 the stock rating was maintained by Jefferies with “Buy”. As per Wednesday, October 5, the company rating was maintained by Deutsche Bank. Deutsche Bank maintained the shares of TROW in report on Monday, August 17 with “Buy” rating. As per Friday, January 8, the company rating was maintained by Deutsche Bank. The firm earned “Buy” rating on Monday, January 8 by Bank of America.

Investors sentiment decreased to 1.72 in Q3 2017. Its down 0.80, from 2.52 in 2017Q2. It is negative, as 12 investors sold Aratana Therapeutics, Inc. shares while 13 reduced holdings. 9 funds opened positions while 34 raised stakes. 31.53 million shares or 1.39% more from 31.10 million shares in 2017Q2 were reported. Franklin Resource invested 0.02% of its portfolio in Aratana Therapeutics, Inc. (NASDAQ:PETX). State Street has 597,904 shares. Moreover, California Public Employees Retirement Systems has 0% invested in Aratana Therapeutics, Inc. (NASDAQ:PETX). Wells Fargo & Mn reported 367,365 shares or 0% of all its holdings. Gp One Trading Lp invested 0% in Aratana Therapeutics, Inc. (NASDAQ:PETX). 790,833 are held by Blair William & Il. 127,800 were reported by Limited Liability Co. Hutchin Hill L P reported 21,300 shares. Ubs Asset Management Americas holds 1,629 shares or 0% of its portfolio. State Of Wisconsin Inv Board reported 29,000 shares stake. General Amer Investors Co Incorporated stated it has 867,600 shares. Goldman Sachs Gru has 0% invested in Aratana Therapeutics, Inc. (NASDAQ:PETX). Moreover, Weiss Multi has 0.01% invested in Aratana Therapeutics, Inc. (NASDAQ:PETX). Morgan Stanley holds 0% in Aratana Therapeutics, Inc. (NASDAQ:PETX) or 88,644 shares. Bridgeway Capital Management reported 134,783 shares.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. The company has market cap of $175.87 million. The Company’s product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. It currently has negative earnings. The firm markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>